GlassScriptPhysician profile
Michele Isaacs
NPI 1851374326
$2,495.95
in general payments reported to CMS, 2019-2025
37 companies · $637 in 2025
The $637 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $96.71 · 2021: $239 · 2022: $374 · 2023: $530 · 2024: $393 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.98 |
| Education | $243.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $530.86 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $276.14 | 2019-2024 | Acessa Provu System, Aptima |
| Amgen INC. | $159.51 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $139.99 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $136.70 | 2023-2025 | Gvoke Hypopen |
| Mayne Pharma Commercial LLC | $109.04 | 2022-2025 | |
| Exeltis, USA INC. | $98.74 | 2021-2025 | Slynd, Nuvessa |
| Agile Therapeutics, INC. | $86.52 | 2021-2023 | Twirla |
| Pfizer INC. | $74.86 | 2019-2023 | |
| Millicent US INC | $71.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $70.05 | 2021-2023 | Steglatro |
| Corcept Therapeutics | $54.19 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $53.34 | 2025 | Myfembree |
| Therapeuticsmd, INC. | $48.28 | 2021-2022 | |
| Allergan, INC. | $43.50 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.27 | 2019-2022 | |
| Evofem Biosciences, INC. | $39.85 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.56 | 2025 | |
| Insulet Corporation | $39.09 | 2023-2025 | Omnipod |
| Novo Nordisk INC | $37.88 | 2020-2024 | Rybelsus |
| Organon LLC | $33.88 | 2023-2025 | Nexplanon |
| Currax Pharmaceuticals LLC | $33.24 | 2024-2025 | Contrave |
| Lilly USA, LLC | $33.21 | 2022-2025 | Zepbound |
| Kerecis Limited | $27.64 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Tandem Diabetes Care, INC. | $27.26 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $24.32 | 2022 | |
| Boston Scientific Corporation | $20.41 | 2019 | |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Meditrina | $17.00 | 2023 | |
| Ascend Therapeutics US, LLC | $16.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.99 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.99 | 2021 | |
| Virtus Pharmaceuticals LLC | $14.61 | 2021 | |
| Assertio Therapeutics, INC. | $13.60 | 2020 | |
| Coopersurgical, INC. | $12.58 | 2022 | |
| Mannkind Corporation | $12.06 | 2020 | |
| Cequr Corporation | $7.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Isaacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.